Hidalgo Medina, Manuel

Publications

Sort by

Co-Author Network

selected publications

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Genome medicine. 2023 Academic Article GET IT
Long COVID in Cancer: A Matched Cohort Study of 1-year Mortality and Long COVID Prevalence Among Patients With Cancer Who Survived an Initial Severe SARS-CoV-2 Infection. American journal of clinical oncology. 2023 Academic Article GET IT
A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker Discovery in Pancreatic Cancer. medRxiv : the preprint server for health sciences. 2023 Article GET IT
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer research communications. 2022 Academic Article GET IT
Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Review GET IT
Times cited: 8
Personalized tumor vaccine for pancreatic cancer. Cancer immunology, immunotherapy : CII. 2022 Academic Article GET IT
Times cited: 1
ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. 2022 GET IT
Times cited: 14
American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. 2022 GET IT
Times cited: 8
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 27
SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers. 2022 Academic Article GET IT
Times cited: 479
Saliva-Based, COVID-19 RT-PCR Pooled Screening Strategy to Keep Schools Open. Disaster medicine and public health preparedness. 2022 Academic Article GET IT
Times cited: 3
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 12
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 16
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021 Academic Article GET IT
Times cited: 58
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 3
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 25
Elevated levels of mitochondrial CoQ₁₀ induce ROS-mediated apoptosis in pancreatic cancer. Scientific reports. 2021 Academic Article GET IT
Times cited: 8
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome medicine. 2021 Academic Article GET IT
Times cited: 7
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021 Editorial Article GET IT
Times cited: 31
Reply to K. de Joode et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Letter GET IT
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. Translational oncology. 2020 Academic Article GET IT
Times cited: 7
PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI insight. 2020 Academic Article GET IT
Times cited: 46
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer cell. 2020 Article GET IT
Times cited: 13
COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 93
Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. JAMA network open. 2020 Academic Article GET IT
Times cited: 19
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Molecular cancer therapeutics. 2020 Academic Article GET IT
Times cited: 23
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature medicine. 2020 Academic Article GET IT
Times cited: 219
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 36
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer cell. 2020 Academic Article GET IT
Times cited: 80
Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Pancreas. 2020 Academic Article GET IT
Times cited: 1
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer management and research. 2019 Academic Article GET IT
Times cited: 108
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature reviews. Clinical oncology. 2019 Review GET IT
Times cited: 188
Reply to I. Pecora et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Letter GET IT
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer cell. 2019 Academic Article GET IT
Times cited: 58
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI insight. 2019 Academic Article GET IT
Times cited: 83
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. American journal of clinical oncology. 2019 Academic Article GET IT
Times cited: 5
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 62
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British journal of cancer. 2018 Academic Article GET IT
Times cited: 51
AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. Drug delivery. 2018 Academic Article GET IT
Times cited: 30
Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. International journal of cancer. 2018 Academic Article GET IT
Times cited: 6
MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. Contrast media & molecular imaging. 2018 Academic Article GET IT
Times cited: 11
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International journal of cancer. 2018 Academic Article GET IT
Times cited: 54
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome medicine. 2018 Academic Article GET IT
Times cited: 46
From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Journal of Cancer. 2018 Review GET IT
Times cited: 23
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 26
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 71
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 38
A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. Molecular cancer therapeutics. 2018 Academic Article GET IT
Times cited: 20
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted oncology. 2018 Academic Article GET IT
Times cited: 48
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer cell. 2018 Academic Article GET IT
Times cited: 69
Personalized RNA Medicine for Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 47
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 55
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal of gastrointestinal oncology. 2017 Academic Article GET IT
Times cited: 40
Patient-derived tumor xenograft models in drug development. Clinical advances in hematology & oncology : H&O. 2017 Article GET IT
Times cited: 1
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. 2017 GET IT
Times cited: 176
Interrogating open issues in cancer medicine with patient-derived xenografts. Nature reviews. Cancer. 2017 Article GET IT
Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. Public health genomics. 2017 Review GET IT
Times cited: 9
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 90
Pancreatic ductal adenocarcinoma: metastatic disease. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017 Review GET IT
Times cited: 7
Management of unresectable, locally advanced pancreatic adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017 Review GET IT
Times cited: 4
Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017 Review GET IT
Times cited: 2
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 125
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 59
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. The oncologist. 2017 Academic Article GET IT
Times cited: 18
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 2017 Academic Article GET IT
Times cited: 43
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature reviews. Cancer. 2017 Review GET IT
Times cited: 459
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2016 Academic Article GET IT
Times cited: 26
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics. 2016 Academic Article GET IT
Times cited: 38
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 293
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. Disease models & mechanisms. 2016 Academic Article GET IT
Times cited: 19
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 27
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British journal of cancer. 2016 Academic Article GET IT
Times cited: 36
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. American journal of clinical oncology. 2016 Academic Article GET IT
Times cited: 5
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nature medicine. 2016 Academic Article GET IT
Times cited: 135
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. Journal of clinical pharmacology. 2016 Academic Article GET IT
Times cited: 9
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular cancer therapeutics. 2016 Academic Article GET IT
Times cited: 40
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016 Review GET IT
Times cited: 24
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Molecular oncology. 2015 Academic Article GET IT
Times cited: 33
Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. PloS one. 2015 Academic Article GET IT
Times cited: 26
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015 Review GET IT
Times cited: 9
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 1325
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 115
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. Cancer research. 2015 Academic Article GET IT
Times cited: 117
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer research. 2015 Academic Article GET IT
Times cited: 112
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 46
Examining the utility of patient-derived xenograft mouse models. Nature reviews. Cancer. 2015 Review GET IT
Times cited: 268
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational new drugs. 2015 Academic Article GET IT
Times cited: 24
Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. Oncotarget. 2015 Academic Article GET IT
Times cited: 33
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut. 2015 Academic Article GET IT
Times cited: 106
Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut. 2015 Academic Article GET IT
Times cited: 102
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 448
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 152
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 35
Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nature medicine. 2014 Letter GET IT
Times cited: 5
Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2014 Review GET IT
Times cited: 335
Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. Nature methods. 2014 Academic Article GET IT
Times cited: 146
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 11
Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. Pharmacology research & perspectives. 2014 Academic Article GET IT
Times cited: 17
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 47
Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer discovery. 2014 Review GET IT
Times cited: 1142
Nab-paclitaxel: a flattering facelift. Critical reviews in oncology/hematology. 2014 Review GET IT
Times cited: 30
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer chemotherapy and pharmacology. 2014 Academic Article GET IT
Times cited: 51
Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 113
Transcriptional dissection of pancreatic tumors engrafted in mice. Genome medicine. 2014 Academic Article GET IT
Times cited: 393
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. American journal of clinical oncology. 2014 Academic Article GET IT
Times cited: 22
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. British journal of cancer. 2014 Letter GET IT
Times cited: 2
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 118
EU Pancreas: an integrated European platform for pancreas cancer research--from basic science to clinical and public health interventions for a rare disease. Public health genomics. 2014 Academic Article GET IT
Times cited: 2
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. International journal of radiation oncology, biology, physics. 2013 Academic Article GET IT
Times cited: 21
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PloS one. 2013 Academic Article GET IT
Times cited: 127
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 4358
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 159
The winning formulation: the development of paclitaxel in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Review GET IT
Times cited: 55
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. British journal of cancer. 2013 Academic Article GET IT
Times cited: 218
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PloS one. 2013 Academic Article GET IT
Times cited: 23
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. International journal of radiation oncology, biology, physics. 2013 Academic Article GET IT
Times cited: 29
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PloS one. 2013 Academic Article GET IT
Times cited: 29
Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology. Current protocols in pharmacology. 2013 Academic Article GET IT
Times cited: 18
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 27
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer letters. 2013 Academic Article GET IT
Times cited: 116
The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology. 2013 Academic Article GET IT
Times cited: 14
Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013 Academic Article GET IT
Times cited: 28
Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 22
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012 Academic Article GET IT
Times cited: 42
New insights into pancreatic cancer biology. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Conference Paper GET IT
Times cited: 59
A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PloS one. 2012 Academic Article GET IT
Times cited: 91
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer medicine. 2012 Academic Article GET IT
Times cited: 12
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Review GET IT
Times cited: 68
Retrospective study assessing the role of MRI in the diagnostic procedures for early breast carcinoma: a correlation of new foci in the MRI with tumor pathological features. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012 Academic Article GET IT
Times cited: 2
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 44
Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. Genome medicine. 2012 Review GET IT
Times cited: 384
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Molecular cancer therapeutics. 2012 Academic Article GET IT
Times cited: 68
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 19
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 18
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. Journal of clinical pathology. 2012 Academic Article GET IT
Times cited: 76
An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics. 2012 Academic Article GET IT
Times cited: 21
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 87
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. The oncologist. 2012 Academic Article GET IT
Times cited: 64
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 184
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. 2011 GET IT
Times cited: 80
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 36
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 29
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature structural & molecular biology. 2011 Academic Article GET IT
Times cited: 291
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 5
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell stem cell. 2011 Academic Article GET IT
Times cited: 312
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 893
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 99
Liver hydatidosis in the present decade. Revista espanola de enfermedades digestivas. 2011 Editorial Article GET IT
Times cited: 5
SMURF1 amplification promotes invasiveness in pancreatic cancer. PloS one. 2011 Academic Article GET IT
Times cited: 50
The inverted pyramid of biomarker-driven trials. Nature reviews. Clinical oncology. 2011 Review GET IT
Times cited: 14
SEOM clinical guidelines for the treatment of pancreatic cancer. 2011 GET IT
Times cited: 4
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 188
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology. 2011 Academic Article GET IT
Times cited: 40
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 320
A DNA methylation fingerprint of 1628 human samples. Genome research. 2011 Academic Article GET IT
Times cited: 295
Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. Annals of surgical oncology. 2011 Academic Article GET IT
Times cited: 19
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 212
Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem cells (Dayton, Ohio). 2011 Academic Article GET IT
Times cited: 77
[Surgical management of familial colorectal cancer type X]. Cirugia espanola. 2011 Letter GET IT
Molecular basis of colorrectal cancer: towards an individualized management?. Revista espanola de enfermedades digestivas. 2011 Review GET IT
Times cited: 18
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. 2010 GET IT
Times cited: 210
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Translational oncology. 2010 Academic Article GET IT
Times cited: 15
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clinical colorectal cancer. 2010 Academic Article GET IT
Times cited: 18
Tumor-initiating cells are rare in many human tumors. Cell stem cell. 2010 Letter GET IT
Times cited: 182
Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. World journal of gastroenterology. 2010 Academic Article GET IT
Times cited: 37
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British journal of cancer. 2010 Academic Article GET IT
Times cited: 66
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Molecular cancer therapeutics. 2010 Academic Article GET IT
Times cited: 77
Pancreatic cancer. The New England journal of medicine. 2010 Review GET IT
Times cited: 2315
SMAD4 in early onset colorectal cancer. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2010 Letter GET IT
Times cited: 1
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 8
[Influence of age on the surgical treatment of lynch syndrome]. Cirugia espanola. 2010 Letter GET IT
Times cited: 2
A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. The Journal of molecular diagnostics : JMD. 2010 Academic Article GET IT
Times cited: 94
Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. BioTechniques. 2010 Academic Article GET IT
Times cited: 26
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. Journal of the National Cancer Institute. 2010 Academic Article GET IT
Times cited: 353
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Molecular cancer therapeutics. 2010 Academic Article GET IT
Times cited: 41
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Critical reviews in oncology/hematology. 2009 Academic Article GET IT
Times cited: 57
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. 2009 GET IT
The hedgehog pathway and pancreatic cancer. The New England journal of medicine. 2009 Academic Article GET IT
Times cited: 102
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer biology & therapy. 2009 Academic Article GET IT
Times cited: 104
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 87
Surgical management of hereditary colorectal cancer: surgery based on molecular analysis and family history. 2009 GET IT
Times cited: 11
Mycophenolate mofetil: An update. Drugs of today (Barcelona, Spain : 1998). 2009 Review GET IT
Times cited: 102
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009 Academic Article GET IT
Times cited: 286
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 29
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Investigational new drugs. 2009 Academic Article GET IT
Times cited: 40
Characterizing DNA methylation patterns in pancreatic cancer genome. Molecular oncology. 2009 Academic Article GET IT
Times cited: 121
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 105
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 859
Fenugreek: a naturally occurring edible spice as an anticancer agent. Cancer biology & therapy. 2009 Academic Article GET IT
Times cited: 81
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2008 Academic Article GET IT
Times cited: 29
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 102
Response to endothelin-1 in arteries from human colorectal tumours: role of endothelin receptors. Experimental biology and medicine (Maywood, N.J.). 2008 Academic Article GET IT
Times cited: 11
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Molecular cancer therapeutics. 2008 Academic Article GET IT
Times cited: 62
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. Journal of proteome research. 2008 Academic Article GET IT
Times cited: 41
Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy. Journal of medicinal chemistry. 2008 Academic Article GET IT
Times cited: 26
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, N.Y.). 2008 Academic Article GET IT
Times cited: 3169
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 26
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 58
New scaffolds for the design of selective estrogen receptor modulators. Organic & biomolecular chemistry. 2008 Academic Article GET IT
Times cited: 26
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 300
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Academic Article GET IT
Times cited: 3
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer biology & therapy. 2008 Academic Article GET IT
Times cited: 158
Methylation alterations are not a major cause of PTTG1 misregulation. BMC cancer. 2008 Academic Article GET IT
Times cited: 4
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer research. 2008 Academic Article GET IT
Times cited: 79
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2008 Academic Article GET IT
Times cited: 29
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 3
Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?. Advances in experimental medicine and biology. 2008 Review GET IT
Times cited: 4
Exploiting novel molecular targets in gastrointestinal cancers. World journal of gastroenterology. 2007 Review GET IT
Times cited: 17
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 138
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatric blood & cancer. 2007 Academic Article GET IT
Times cited: 8
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clinical pharmacology and therapeutics. 2007 Academic Article GET IT
Times cited: 46
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 41
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 1037
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 272
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Academic Article GET IT
Times cited: 9
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 16
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer chemotherapy and pharmacology. 2007 Academic Article GET IT
Times cited: 35
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer biology & therapy. 2007 Academic Article GET IT
Times cited: 173
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. British journal of cancer. 2007 Academic Article GET IT
Times cited: 74
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 27
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 29
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 22
The Development of rapamycin as an orphan drug. Clinical advances in hematology & oncology : H&O. 2007 Academic Article GET IT
Times cited: 1
EGFR inhibitor-mediated apoptosis in solid tumors. Journal of experimental therapeutics & oncology. 2007 Review GET IT
Times cited: 35
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 21
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. Journal of the National Cancer Institute. 2006 Academic Article GET IT
Times cited: 94
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006 Academic Article GET IT
Times cited: 219
Assessment of celecoxib pharmacodynamics in pancreatic cancer. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 31
Novel targets in solid tumors: MEK inhibitors. Clinical advances in hematology & oncology : H&O. 2006 Review GET IT
Times cited: 36
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 89
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 206
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochimica et biophysica acta. 2006 Review GET IT
Times cited: 48
An in vivo platform for translational drug development in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 371
Cetuximab in squamous cell carcinoma of the head and neck. Future oncology (London, England). 2006 Review GET IT
Times cited: 5
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 25
Multitargeted therapy: can promiscuity be praised in an era of political correctness?. Critical reviews in oncology/hematology. 2006 Review GET IT
Times cited: 32
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 11
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Investigational new drugs. 2006 Academic Article GET IT
Times cited: 74
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Academic Article GET IT
Times cited: 46
Targeting mTOR for cancer treatment. Current opinion in investigational drugs (London, England : 2000). 2006 Review GET IT
Times cited: 54
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 129
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 139
Benzoylphenylurea sulfur analogues with potent antitumor activity. Journal of medicinal chemistry. 2006 Academic Article GET IT
Times cited: 42
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Molecular cancer therapeutics. 2006 Review GET IT
Times cited: 83
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 16
C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer research. 2006 Academic Article GET IT
Times cited: 32
Targeting mTOR for cancer treatment. Advances in experimental medicine and biology. 2006 Review GET IT
Times cited: 27
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer biology & therapy. 2005 Academic Article GET IT
Times cited: 35
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Molecular cancer therapeutics. 2005 Academic Article GET IT
Times cited: 30
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 10
Current status of mammalian target of rapamycin inhibitors in lung cancer. Clinical lung cancer. 2005 Review GET IT
Times cited: 14
Treating cancer by blocking cell signals. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Editorial Article GET IT
Times cited: 12
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. Expert review of anticancer therapy. 2005 Review GET IT
Times cited: 1
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 647
Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 167
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer biology & therapy. 2005 Academic Article GET IT
Times cited: 114
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 Academic Article GET IT
Times cited: 70
Design, synthesis and biological evaluation of novel riccardiphenol analogs. Bioorganic & medicinal chemistry. 2005 Academic Article GET IT
Times cited: 18
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer research. 2005 Academic Article GET IT
Times cited: 97
Blockade of epidermal growth factor receptor (EGFR) activity. Critical reviews in oncology/hematology. 2005 Review GET IT
Times cited: 24
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 107
Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer research. 2005 Academic Article GET IT
Times cited: 85
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer research. 2004 Academic Article GET IT
Times cited: 242
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 355
Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clinical lung cancer. 2004 Review GET IT
Times cited: 17
The V599E BRAF mutation is uncommon in biliary tract cancers. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2004 Academic Article GET IT
Times cited: 41
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 62
Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 91
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 84
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 159
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast cancer research : BCR. 2004 Review GET IT
Times cited: 92
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 108
New target, new drug, old paradigm. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Editorial Article GET IT
Times cited: 18
Synthesis and antitumor evaluation of benzoylphenylurea analogs. Bioorganic & medicinal chemistry letters. 2004 Academic Article GET IT
Times cited: 30
Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clinical colorectal cancer. 2004 Review GET IT
Times cited: 13
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 891
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 754
Erlotinib: preclinical investigations. Oncology (Williston Park, N.Y.). 2003 Review GET IT
Times cited: 39
Progress in the development and acquisition of anticancer agents from marine sources. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Review GET IT
Times cited: 128
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer research. 2003 Academic Article GET IT
Times cited: 129
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Academic Article GET IT
Times cited: 58
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 178
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 67
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. The American journal of pathology. 2003 Academic Article GET IT
Times cited: 114
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 123
Developing inhibitors of the epidermal growth factor receptor for cancer treatment. Journal of the National Cancer Institute. 2003 Review GET IT
Times cited: 329
Development of the epidermal growth factor receptor inhibitor OSI-774. Seminars in oncology. 2003 Review GET IT
Times cited: 50
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Seminars in oncology. 2003 Review GET IT
Times cited: 95
Recent advances in the pharmacological treatment of colorectal cancer. Expert opinion on investigational drugs. 2003 Review GET IT
Times cited: 8
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Advances in experimental medicine and biology. 2003 Review GET IT
Times cited: 53
Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods in molecular medicine. 2003 Review GET IT
Times cited: 8
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer research. 2002 Academic Article GET IT
Times cited: 269
Development of matrix metalloproteinase inhibitors in cancer therapy. Hematology/oncology clinics of North America. 2002 Review GET IT
Times cited: 22
Promising developments in targeted therapies for non-small-cell lung cancer. Clinical lung cancer. 2002 Academic Article GET IT
Times cited: 2
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 32
Angiogenesis inhibitors in clinical development for lung cancer. Seminars in oncology. 2002 Review GET IT
Times cited: 51
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 82
An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer biology & therapy. 2002 Review GET IT
Times cited: 49
New targets for cancer chemotherapy. Cancer chemotherapy and biological response modifiers. 2002 Academic Article GET IT
Times cited: 2
Pancreatic cancer. Current problems in cancer. 2002 Review GET IT
Times cited: 246
The epidermal growth factor receptor: a new target for anticancer therapy. Current problems in cancer. 2002 Review GET IT
Times cited: 53
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 35
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 973
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 38
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 43
Matrix metalloproteinase inhibitors: how can we optimize their development?. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Editorial Article GET IT
Times cited: 22
Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute. 2001 Review GET IT
Times cited: 743
Therapeutic angiogenesis inhibitors in the treatment of cancer. Advances in internal medicine. 2001 Review GET IT
Times cited: 9
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000 Review GET IT
Times cited: 562
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 51
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 11
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 22
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 79
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anti-cancer drugs. 1999 Academic Article GET IT
Times cited: 24
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. The Journal of antimicrobial chemotherapy. 1999 Academic Article GET IT
Times cited: 28
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anti-cancer drugs. 1999 Academic Article GET IT
Times cited: 39
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay. Anti-cancer drugs. 1999 Academic Article GET IT
Times cited: 3
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 176
New anticancer agents. Cancer chemotherapy and biological response modifiers. 1999 Review GET IT
Times cited: 1
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999 Academic Article GET IT
Times cited: 103
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 48
A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998 Academic Article GET IT
Times cited: 14
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1998 Academic Article GET IT
Times cited: 42
[Surgical treatment of hepatolithiasis. Presentation of a case]. Revista espanola de enfermedades digestivas. 1998 Letter GET IT
Times cited: 5
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 16
Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 15
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 29
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrobial agents and chemotherapy. 1997 Academic Article GET IT
Times cited: 19
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 9
Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. Journal of the National Cancer Institute. 1996 Letter GET IT
Times cited: 6
[Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants]. Medicina clinica. 1996 Review GET IT
Times cited: 5
Comparative study of infectious complications of different types of chronic central venous access devices. Cancer. 1995 Letter GET IT
Times cited: 4
Successful treatment of candida peritonitis with fluconazole. The Journal of antimicrobial chemotherapy. 1994 Letter GET IT
Times cited: 7
Ventricular arrhythmias with conventional and liposomal amphotericin. Lancet (London, England). 1993 Letter GET IT
Times cited: 28
[Incidence and surgical treatment of extrahepatic abdominal hydatidosis]. Revista espanola de enfermedades digestivas. 1992 Academic Article GET IT
Times cited: 11
[Manometric changes induced by antireflux surgery (Nissen) and its relation to pH measurement and clinical findings. An analysis 6 months after the intervention]. Revista espanola de enfermedades digestivas. 1992 Academic Article GET IT
Times cited: 1
[Sphincterotomy and sphincteroplasty: a comparative study in a series of 257 patients]. Revista espanola de las enfermedades del aparato digestivo. 1986 Academic Article GET IT

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

A bioengineered model of tumor vessel interactions in pancreatic cancer awarded by National Institute of General Medical Sciences Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

M.Sc., Harvard University 2017
Ph.D., Autonomous University of Madrid, Faculty of Medicine (Spain) 1997
M.D., University of Navarra Faculty of Medicine (Spain) 1992

Contact

full name

Manuel Hidalgo Medina

primary email

mah4006@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Manuel Hidalgo Medina Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage